Department of Medical Cell Biology, University of Marburg, 35032, Marburg, Germany.
Department of Anatomy and Cell Biology III, University of Heidelberg, 69120, Heidelberg, Germany.
BMC Cardiovasc Disord. 2020 Sep 17;20(1):420. doi: 10.1186/s12872-020-01703-x.
Effects of re-supplementation of a cholesterol-enriched diet (CEDrs) on size, cholesterol content and morphology of already existing plaques are not known to date.
A group of rabbits received standard chow (SC) for 6 weeks ("negative control"; for plasma lipid measurements only). Group I-IV received 2% CED (induction) for 6 weeks; thereafter, groups II-IV have been fed a SC (= cholesterol withdrawal) for 68 weeks. Afterwards, feeding of groups II-IV was continued as follows: Group II - 10 weeks SC, group III - 4 weeks 0.5% CED (re-supplementation), afterwards 6 weeks SC (withdrawal again); group IV - 4 weeks 0.5% CED (re-supplementation) + atorvastatin (2.5 mg/kg body weight/day), afterwards 6 weeks SC (~withdrawal again) + atorvastatin. Plasma lipids, but also plaque size, morphology and cholesterol contents of thoracic aortas were quantified.
After CEDrs, plasma cholesterol levels were increased. However, after withdrawal of CEDrs, plasma cholesterol levels decreased, whereas the cholesterol content of the thoracic aorta was increased in comparison with the group without CEDrs. Plaque size remained unaffected. Atorvastatin application did not change plasma cholesterol level, cholesterol content of the thoracic aorta and plaque size in comparison with the group without drug treatment. However, atorvastatin treatment increased the density of macrophages (MΦ) compared with the group without treatment, with a significant correlation between densities of MΦ (Mac-1) and apoptotic (TUNEL; TP53), antigen-presenting (HLA-DR) or oxidatively stressed (SOD2) cells.
In rabbits with already existing plaques, CEDrs affects plaque morphology and cellular composition, but not plaque size. Despite missing effects on plasma cholesterol levels, cholesterol content of the thoracic aorta and size of already existing atherosclerotic plaques, atorvastatin treatment transforms the already existing lesions to a more active form, which may accelerate the remodelling to a more stable plaque.
目前尚不清楚重新补充富含胆固醇的饮食(CEDrs)对已存在斑块的大小、胆固醇含量和形态的影响。
一组兔子接受标准饮食(SC) 6 周(仅用于血浆脂质测量)。I-IV 组接受 2% CED(诱导)6 周;此后,组 II-IV 连续 68 周喂食 SC(=胆固醇撤出)。之后,继续对组 II-IV 进行以下喂养:组 II - 10 周 SC,组 III - 4 周 0.5% CED(≈再补充),然后 6 周 SC(≈再次撤出);组 IV - 4 周 0.5% CED(再补充)+阿托伐他汀(2.5mg/kg 体重/天),然后 6 周 SC(≈再次撤出)+阿托伐他汀。定量检测胸主动脉的血浆脂质,但也包括斑块大小、形态和胆固醇含量。
CEDrs 后,血浆胆固醇水平升高。然而,撤出 CEDrs 后,血浆胆固醇水平降低,而与未接受 CEDrs 的组相比,胸主动脉的胆固醇含量增加。斑块大小保持不变。与未接受药物治疗的组相比,阿托伐他汀的应用并未改变血浆胆固醇水平、胸主动脉的胆固醇含量和斑块大小。然而,与未治疗的组相比,阿托伐他汀治疗增加了巨噬细胞(MΦ)的密度,并且 MΦ(Mac-1)、凋亡(TUNEL;TP53)、抗原呈递(HLA-DR)或氧化应激(SOD2)细胞的密度之间存在显著相关性。
在已经存在斑块的兔子中,CEDrs 会影响斑块形态和细胞组成,但不影响斑块大小。尽管阿托伐他汀治疗对血浆胆固醇水平、胸主动脉胆固醇含量和已存在动脉粥样硬化斑块的大小没有影响,但它将已存在的病变转化为更活跃的形式,这可能会加速向更稳定的斑块的重塑。